Alex Andrianopoulos Email and Phone Number

At Kairos Ventures we are optimists about the future because we invest in hard-tech, technology-driven startups that tackle hard, global challenges -- and will make the world a better place.I have been running deal sourcing, deal diligence and deal structuring at Kairos since its founding in 2015, when I designed the processes and recruited the teams for those functions. My focus is on honing our identification, diligence and investment processes so that we invest in the best scientific opportunities, with a goal to build a portfolio of startups with global positive impact while also delivering robust returns to our LPs.I engage personally with our founders through active participation on their boards and by rolling up my sleeves and guiding founders in their journey through startup creation, strategy definition, fundraising, recruiting, and business development.

Actinia builds detectors for highly efficient detection of gamma rays and X-rays, allowing reduced radiation dose without loss of any resolution. Invented in Professor Mercouri Kanatzidis’ laboratory at Northwestern, Actinia’s innovative materials offer higher X-ray sensitivity, better gamma-ray energy resolution, and lower production costs than competing materials in the field.

Vivodyne revolutionizes the discovery and development of therapeutics through the combination of AI, wet labs, automation, and robotics, massively scaling up the testing of drugs on lab-grown human tissues.

Applaud Medical is a clinical-stage company offering an innovative, non-invasive treatment for kidney stones, a condition afflicting 2 million people in the US every year. Currently, the least-invasive surgical intervention only renders 50% of patients stone-free and it requires undergoing an operation at a hospital OR under full or partial anesthesia. Applaud’s innovative kidney stone treatment will – for the first time – allow urologists to effectively treat 5-10 mm stones with a simple outpatient procedure at a doctor's office.

NVasc, Inc. is an early-stage ophthalmology company focused on the treatment of ischemic eye diseases, such as age-related macular degeneration and diabetic retinopathy with a novel method promoting healthy vascularization of diseased tissues.

Siege Pharmaceuticals is developing cancer therapeutics that their method of action is a complete blockade of nutrition pathways to cancel cells

Actinobac is a biopharmaceutical company developing therapeutics for cancer and auto-immune diseases with a molecule targeting activated white blood cells. Following pre-clinical studies demonstrating safety and efficacy, Actinobac has now received FDA clearance to proceed with first-in-human trials of its novel therapeutic.

Pinpoint Therapeutics is developing novel cancer treatments through inhibiting autophagy, a key cell function highjacked by cancer cells to promote their survival and key cause of treatment resistance.

Actuate Therapeutics is a clinical stage therapeutics company focusing on the treatment of difficult to treat cancers. It is developing novel therapeutics that target Glycogen Synthase Kinase-3β (GSK-3β). Activity and overexpression of GSK-3β have been implicated in many conditions, including cancer, Alzheimer’s disease, bipolar disorder, and inflammatory conditions leading to fibrosis.

Novosteo is developing novel therapeutics for the treatment of bone injury and diseases that impact patient mobility and productivity. Novosteo's lead compounds are bone-targeted drugs that preferentially accumulate in fracture sites and accelerate bone regeneration by delivering anabolic agents preferentially to fracture surfaces.

KMLabs is the leading provider of the world’s most advanced femtosecond lasers, claiming the top universities and research institutions worldwide as its customers. KMLabs supplies advanced systems to research, government, and industrial markets.

Xidas is a next-generation industrial component company that designs and manufactures a new breed of micro-devices for high-value markets such as telecom, aerospace, manufacturing, and medicine. Through a powerful new manufacturing paradigm (Amalga™), Xidas has surpassed the limitations of current micro-manufacturing, allowing the production of products that could not have been built before.

Advising this high growth startup specializing on Big Data Analytics on business development, corporate development, sales, and marketing strategy

Responsible for accelerating the growth of our company -- an industry leader in delivering BI on Hadoop / Big Data -- through developing global strategic partnerships with our Hadoop distro and hosting partners, our BI front-end partners, and our SI partners.AtScale empowers business analysts to analyze massive amounts of data residing in Hadoop data hubs at the speed of thought. With AtScale, analysts can query, interact, pivot, drill-down, analyze and visualize terabytes and petabytes of Hadoop data with sub-second response times. AtScale enables direct access to Hadoop data without requiring ETL or data movement. Instead, business analysts connect through their familiar BI tools (Tableau, Qlik, Excel, etc.) to AtScale, which then queries Hadoop data in place so that analysts can interact with the data through familiar multi-dimensional constructs, like dimensions and measures. AtScale turns your Hadoop data hub into an OLAP server for business intelligence analysis and reporting. To learn more about how you can maximize your investment in Hadoop with AtScale go to www.atscale.com.

Leader of the Marketing team globally, with responsibility for all Marketing and Business Development functions, including Lead Generation, Lead Management, Product Marketing, PR/AR, Channel Marketing, Event Management, Web Marketing, Field Marketing, Business Development, and Strategic Partnerships.

Led the Product Marketing team for Oracle’s $7B+ Fusion Middleware portfolio of products, including Security, Identity Management, Data Management, Business Process Management, and Application Server. Responsible for developing the go-to-market strategy and devising plans and tactics to ensure a tightly coordinated and synchronized approach across all Fusion Middleware products, including strategic fit, product alignment, sales and marketing integration for dozens of acquisitions ranging in valuation from a few million to multi-billion dollars.

Directed a comprehensive market research effort for a luxury product category in the CPG domain and leveraged the results to create the firm’s overall strategy primarily consisting of product definition, brand creation, branding strategy, communications and advertising.

Member of SeeBeyond's senior executive team that took the company public and grew the company from less than 400 employees to more than 800, from 500 customers to 2000+, and with $200 million annual revenues by the time it was acquired by Sun Microsystems.Owned the functions of product management, product marketing, product strategy and planning, and intellectual property protection; key reference implementations and knowledge propagation programs; and standards participation.

Member of the executive team successfully raising $21 million in venture capital over two rounds of funding. Helped secure MineShare’s first customer and grow the customer base across the nation.